4D Molecular Therapeutics, Inc. (FDMT)
| Previous close | 23.97 |
| Open | 24.37 |
| Bid | 24.71 x 200 |
| Ask | 25.00 x 200 |
| Day's range | 23.81 - 25.40 |
| 52-week range | 9.44 - 36.25 |
| Volume | |
| Avg. volume | 601,244 |
| Market cap | 1.287B |
| Beta (5Y monthly) | 2.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.36 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 52.30 |
GlobeNewswire4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in June. Members of the management team will also be available for one-on-one meetings. Jefferies Global Healthcare Conference Presentation
- GlobeNewswire
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
Interim clinical data will be presented by Jennifer L. Taylor-Cousar, M.D., Principal Investigator of the AEROW clinical trial at the 47th European Cystic Fibrosis Conference on Thursday, June 6, 2024 at 5:00 p.m. BSTCompany to host webcast on Thursday, June 6, 2024 at 8:00 a.m. ET EMERYVILLE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic
Simply Wall St.We're Interested To See How 4D Molecular Therapeutics (NASDAQ:FDMT) Uses Its Cash Hoard To Grow
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
